GENMAB A/S
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Large accelerated filer
Business Address TOLDBODGADE 33, 1253 COPENHAGEN K, G7, 00000
Mailing Address TOLDBODGADE 33, 1253 COPENHAGEN K, G7, 00000
EIN 000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | March 30, 2026 | View on SEC |
| 6-K Foreign company current report | March 23, 2026 | View on SEC |
| 6-K Foreign company current report | March 19, 2026 | View on SEC |
| 6-K Foreign company current report | March 19, 2026 | View on SEC |
| 6-K Foreign company current report | March 16, 2026 | View on SEC |
| 6-K Foreign company current report | March 9, 2026 | View on SEC |
| 6-K Foreign company current report | March 4, 2026 | View on SEC |
| 6-K Foreign company current report | March 3, 2026 | View on SEC |
| 6-K Foreign company current report | March 2, 2026 | View on SEC |
| 6-K Foreign company current report | February 27, 2026 | View on SEC |
Annual Reports
20-F February 17, 2026
- Achieved robust 25% revenue growth to approximately $2.2 billion in 2023, driven by strong product sales and DARZALEX® royalties.
- Reported a solid net profit of approximately $650 million and maintained a healthy cash position of around $1.5 billion.
Related Companies
Companies in the same industry (SIC: 2834)
NERVGEN PHARMA CORP.
NGEN Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB Pharmaceutical Preparations
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV
HURA Pharmaceutical Preparations
Canton Strategic Holdings, Inc.
CNTN Pharmaceutical Preparations
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.